GEM333 / AvenCell Therap, BMS - LARVOL DELTA

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - P1 | N=36 | Terminated | Sponsor: AvenCell Europe GmbH | Trial completion date: Dec 2020 ➔ Jun 2022 | Unknown status ➔ Terminated | Trial primary completion date: Jul 2020 ➔ Jun 2022; The actions and measures to be taken to restart the trial could not be implemented which made the premature termination inevitability.

Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - P1; N=33; Active, not recruiting; Sponsor: GEMoaB Monoclonals GmbH; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33

Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia (clinicaltrials.gov) - P1; N=33; Recruiting; Sponsor: GEMoaB Monoclonals GmbH; Trial completion date: Dec 2019 ➔ Dec 2020; Trial primary completion date: Oct 2019 ➔ Jul 2020

Clinical • Trial completion date • Trial primary completion date

DARTS, Bites and ADCs for the Treatment of AML and for Conditioning for Allogeneic Stem Cell Transplantation (SOHO 2019) - "These include JNJ-63709178; (target: CD123; trial suspended), XmAb14045; (target: CD123), Flotetuzumab/DART; (target: CD123) as well as others focused on CD33 (AMG330, AMG673, AMV564, GEM333) and CLL-1 (MCLA-117). Additional correlative studies will be presented for this and other AML bispecifics currently being tested by our and other groups in the clinic. Finally, we will present data on the use of ADCs for the treatment of AML in vitro and for conditioning for stem cell transplantation within and across MHC barriers using mouse preclinical transplant models."

IO Biomarker